1

Bachem

#2518

Rank

$5.84B

Marketcap

CH Switzerland

Country

Bachem
Leadership team

Mr. Thomas Meier (Chief Exec. Officer)

Mr. Alain Schaffter (Chief Financial Officer)

Dr. Thomas Fruh (Sec.)

Products/ Services
Chemical
Number of Employees
1,000 - 20,000
Headquarters
Bubendorf, Basel-Landschaft, Switzerland
Established
1971
Net Income
100M - 500M
Revenue
500M - 1B
Traded as
BANB.SW
Social Media
Overview
Location
Summary
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland.
History

In 1971, Peter Grogg founded Bachem Feinchemikalien AG with two employees in Liestal near Basel with the focus on peptide synthesis. In 1977, Bachem moved with eight employees to nearby Bubendorf, and, in 1978, it manufactured, for the first time, peptides for use in medicine under cGMP guidelines. Between 1981 and 1991 Bachem tripled its production capacity and built an administration building, and in 1995, facilities were further expanded including the quality control department to a total of 168'000 sq. ft. .

Expansion into markets outside Europe began with the establishment of Bachem Bioscience, Inc. in Philadelphia, USA in 1987. To strengthen its presence in Europe, Bachem opened sales and marketing centers in Germany in 1988 and in France in 1993. In 1996 it acquired its largest competitor, Bachem, Inc., together with its subsidiaries in Germany and the United Kingdom. In June 1998, following a very successful IPO, Bachem's shares began to be publicly traded on the Swiss Stock Exchange. In 1999 and 2000, a new administration building and a further production facility were respectively opened at the Bubendorf site.

With the acquisition of the San Carlos, California based Peninsula Laboratories, Inc. and its affiliate Peninsula Laboratories Ltd., United Kingdom in December 1999, Bachem extended its strong position in therapeutically active peptides into immunology, a domain with strong future promise. In August 2000, Peninsula Laboratories Europe Ltd. and Bachem Ltd. merged to a single Bachem group affiliated company in the United Kingdom.

The acquisition of Sochinaz SA, a Swiss-based specialized manufacturer of active pharmaceutical ingredients in 2001, strengthened Bachem's expertise and once again expanded its manufacturing capabilities.

Reorganization of distribution was carried out in Germany and France as a result of the positive experiences gained with the realignment of the sales and marketing organization in the USA. As a result, the subsidiary in France was closed at the end of 2002. The subsidiary in Germany was relocated from Heidelberg to Weil am Rhein, was renamed Bachem Distribution Services GmbH and is now responsible for all customers in the European Union.

In 2003, a holding structure was introduced to align the factual organization of the company with an appropriate legal structure and to support management structure adjustments, given by continued company growth requirements. In 2010, Bachem commenced the partnership with Atheris laboratories offering the Melusine® range of research products for lead generation of new pharmaceutical candidates. In 2011, Bachem celebrated its 40th year as a producer of research ingredients and active pharmaceutical ingredients for the pharmaceutical industry.

In 2013, Bachem and GlyTech Inc. teamed up to offer glycosylated peptides in their product pipelines. Bachem and affiliate were conducting groundbreaking work on interferon beta-1a and to manufacture glycosylated somatostatin analogues by chemical synthesis.In 2015, Bachem acquired American Peptide Company, a mid-sized biotech establishment in Sunnyvale CA, not far from Bachem's US facility in Torrance, expanding the firm's GMP manufacturing and R&D capabilities for the US and international markets.

Mission
At Bachem, we strive to provide our clients and partners with the highest quality peptides, peptide-related products and services that can enable their research and development efforts. We will continue to stay at the forefront of peptide technology and will work continuously to develop and offer innovative products and services.
Vision
At Bachem, we aim to be the premier peptide supplier, recognized worldwide for its quality products, reliable commitment, and long-term customer relationships.
Key Team

Dr. Gunther Loidl (Chief Technology Officer)

Mr. Roland Schürmann (Chief Operations Officer)

Mr. Michael Suter (VP of Global Accounting)

Dr. Christian Stähelin (Director of HR)

Mr. Jean-Marc Fellay (VP of Fin. & HR)

Mr. Michael Staroverov (Group Chief Information Officer)

Mr. Torsten Wöhr (Chief Marketing Officer)

Recognition and Awards
Bachem has consistently been recognized for its excellence in the industry, recently receiving a GMP Certificate from the Swiss Agency for Therapeutic Products in 2008, a “Technology Pioneer” award from the World Economic Forum in 2009, and an “Innovator” award from the European Peptide Society in 2011.
References
Bachem
Leadership team

Mr. Thomas Meier (Chief Exec. Officer)

Mr. Alain Schaffter (Chief Financial Officer)

Dr. Thomas Fruh (Sec.)

Products/ Services
Chemical
Number of Employees
1,000 - 20,000
Headquarters
Bubendorf, Basel-Landschaft, Switzerland
Established
1971
Net Income
100M - 500M
Revenue
500M - 1B
Traded as
BANB.SW
Social Media